Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Last trade$13.17
Day change-$0.33 (-2.44%)
Day range$12.92 – $13.82
Volume91,410
Market cap$564M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$564.1M
Price / earnings
—
Price / book
2.06×
Price / sales
37.61×
EV / sales
18.32×
EV / EBITDA
-1.51×
Profitability
Earnings per share
-$3.83
Return on assets
-53.47%
Return on equity
-58.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
12.57×
Quick ratio
12.57×
Cash ratio
12.32×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$82.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CBIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q3 FY2023 Sep 30, 2023
Q2 FY2023 Jun 30, 2023
Revenue
$3.12M
$0
$1.04M
$10.84M
$0
$0
$32.04M
$29.33M
Cost of revenue
$0
$0
$0
$0
$0
$0
$1.18M
$1.08M
Gross profit
$3.12M
$0
$1.04M
$10.84M
$0
$0
$30.86M
$28.25M
Selling, general and administrative
$8.72M
$8.74M
$7.87M
$7.31M
$5.54M
$8.95M
$15.09M
$19.71M
Research and development
$34.31M
$19.39M
$17.9M
$95.03M
$20.35M
$12.08M
$3.01M
$3.57M
Total operating expenses
$43.02M
$26.36M
$25.77M
$102.34M
$25.89M
$21.03M
$18.09M
$23.28M
Operating income
-$39.91M
-$26.36M
-$24.73M
-$91.49M
-$25.89M
-$21.03M
$12.76M
$4.97M
Interest expense
$0
$0
$0
$0
$0
-$1.07M
$0
$251K
Income before taxes
-$37.73M
-$24.84M
-$23.28M
-$90.4M
-$24.61M
-$21.79M
$11.19M
$5.85M
Income taxes
$0
$0
$0
$2M
$0
$0
$3.68M
$2.08M
Net income
-$37.73M
-$24.84M
-$23.28M
-$92.4M
-$24.61M
-$21.79M
$7.51M
$3.77M
Net income attributable to common shareholders
-$35.13M
-$22.69M
-$21.26M
-$81.06M
-$20.95M
-$19M
$3.98M
$1.85M
EBITDA
-$39.84M
-$26.3M
-$24.67M
-$91.44M
-$25.86M
-$21.03M
$12.96M
$5.28M
Basic earnings per share
-$0.90
-$0.74
-$0.70
-$3.96
-$1.27
-$4.93
$0.06
$0.03
Diluted earnings per share
-$0.90
-$0.74
-$0.70
-$3.96
-$1.27
-$4.93
$0.05
$0.02
Recent news
Company coverage with links to the original publishers.
Crescent Biopharma reported Q2 2026 results with continued enrollment in its ASCEND Phase 1/2 trial for CR-001, a PD-1 x VEGF bispecific antibody. The company completed a $143.7 million public offering extending cash runway to H2 2028 and announced multiple clinical data readouts expected beginning Q1 2027. R&D expenses increased to $19.4 million due to expanded clinical activities, while the company maintains strategic partnerships with Kelun-Biotech for development in Greater China.
Crescent Biopharma (Nasdaq: CBIO), a clinical-stage oncology biotechnology company, announced the pricing of an underwritten public offering of 8.1 million ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 per warrant, expected to raise approximately $125 million in gross proceeds. The offering is expected to close on July 16, 2026, with underwriters granted a 30-day option to purchase an additional 1.3 million shares.
The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023
Gainers
Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ.
Nuvve Holding Corp. (NASDAQ: NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share.
BIO-key International, Inc. (NASDAQ: BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023.
ReShape Lifesciences Inc. (NASDAQ: RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million public offering.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares climbed 37.6% to $3.2199 after announcing positive findings from an independent third party audit of the data integrity at TRANQUILITY II Phase 3 trial site.
ParaZero Technologies Ltd. (NASDAQ: PRZO) gained 26% to $2.0350.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) climbed 18% to $0.5095.
Scholar Rock Holding Corporation (NASDAQ: SRRK) gained 16.5% to $8.92. Jefferies upgraded Scholar Rock from Hold to Buy and announced a $20 price target.
Stride, Inc. (NYSE: LRN) rose 16.4% to $51.81 after the company reported first-quarter results.
OncoCyte Corporation (NASDAQ: OCX) gained 14.4% to $2.86.
Urgent.ly Inc. (NASDAQ: ULY) surged 14% to $5.01.
GameSquare Holdings, Inc. (NASDAQ: GAME) gained 13.1% to $2.07.
Treasure Global Inc. (NASDAQ: TGL) rose 12.8% to $0.4501.
PROG Holdings, Inc. (NYSE: PRG) rose 9.3% to $31.14 following upbeat quarterly results.
LumiraDx Limited (NASDAQ: LMDX) gained 8.4% to $0.1680 after dipping around 44% on Tuesday.
John Bean Technologies Corporation (NYSE: JBT) surged 8.1% to $104.00 after posting strong quarterly earnings.
Sonendo, Inc. (NYSE: SONX) shares gained 8% to $0.2483 after falling over 23% on Tuesday. Sonendo recently announced preliminary revenue results for the third quarter.
Crown ElectroKinetics Corp. (NASDAQ: CRKN) climbed 8% to $0.2700.
Deutsche Bank Aktiengesellschaft (NYSE: DB) rose 6.6% to $10.72 after the company reported a year-over-year increase in third-quarter EPS and sales results.
Deutsche Bank Aktiengesellschaft (NYSE: DB) gained 6.6% to $10.72 after the company reported a year-over-year increase in third-quarter EPS and sales results.
The Gap, Inc. (NYSE: GPS) climbed 6.2% ...
Gainers
INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.
LumiraDx Limited (NASDAQ: LMDX) shares climbed 187.4% to $0.25 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.
Akumin Inc. (NASDAQ: AKU) shares climbed 125% to $0.3279 after the company reached an agreement with Stonepeak to become a private company.
Textainer Group Holdings Limited (NYSE: TGH) shares gained 44.5% to $49.33 after the company agreed to be acquired by Stonepeak for $7.4 billion.
Twin Ridge Capital Acquisition Corp. (NYSE: TRCA) climbed 17.7% to $8.11.
Bright Green Corporation (NASDAQ: BGXX) rose 17.6% to $0.4156.
Navios Maritime Holdings Inc. (NYSE: NM) gained 17.2% to $2.21. N Logistics Holdings announced plans to acquire all outstanding shares of common stock of Navios Maritime Holdings not already owned by NLHC for $2.28 per share.
Motus GI Holdings, Inc. (NASDAQ: MOTS) gained 16.2% to $0.5576.
TeraWulf Inc. (NASDAQ: WULF) rose 16% to $1.2775
FLJ Group Limited (NASDAQ: FLJ) jumped 15.8% to $0.3323.
NOVONIX Limited (NASDAQ: NVX) climbed 15.4% to $2.10
The Alkaline Water Company Inc. (NASDAQ: WTER) shares rose 14.6% to $0.2290 after falling 14% on Friday.
Nexalin Technology, Inc. (NASDAQ: NXL) surged 13.6% to $0.3580.
Farfetch Limited (NYSE: FTCH) rose 13% to $1.7850.
EngageSmart, Inc. (NYSE: ESMT) gained 12.1% to $22.65 after the company announced it would be acquired by Vista Equity Partners for $23 per share.
Digital Brands Group, Inc. (NASDAQ: DBGI) rose 11.2% to $5.36.
Abacus Life, Inc. (NASDAQ: ABL) climbed 8.4% to $6.81.
Riot Platforms, Inc. (NASDAQ: RIOT) shares gained ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.